RE:JV with Merck's Keyteuda a bad idea...I like the $200.00 target price, Theralase will get there one day.
As for immunotherapy, TLT compound(Rutherrin) work with Immunotherapy as specified in this link.
2024-06-18 | Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically | TSXV:TLT | Press Release And immunotherapy market is approximately US125 Billion a year, and Theralase will certainly one day grab a chunk of it.
gojotv! wrote: When business hounds try Science, crazy ideas abound. I'm reading here that some want to JV with Merck and "combo" Ruvidar with Keytruda...
The idea doesn't work on so many levels.
First, Keytruda is an immunotherapy, where Ruvidar is a targeted cancer killer.
Second, Keytruda's patent expires in a couple of years, before Ruvidar's usefulness in other cancer therapies can be fully developed.
Also, Keytruda has toxicities which Ruvidar aims to eliminate from oncology.
And most of all, Ruvidar is currently being tested in a "two treatment" protocol, which limits our results. In the real world, patients will be able to get Rividar until their cancer is destroyed - any time after the first treatment. Can you imagine how our "partial response" patients would do after 4 or 5 treatments? They'd be cancer-free, IMO.
So, enough with the crazy talk, let's aim for "Ruvidar - exclusive" treatment protocols, and a $200 share price.
And that is all.
Happy Holidays!